To include your compound in the COVID-19 Resource Center, submit it here.

Zealand's glepaglutide meets in Phase II for SBS

Zealand Pharma A/S (CSE:ZEAL) reported data from a Phase II trial in 16 patients with short bowel syndrome (SBS) showing that once-daily subcutaneous glepaglutide (ZP1848) met

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE